skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Long-term disease-free survivor of metastatic large-cell neuroendocrine carcinoma of the lung treated with amrubicin and irinotecan

Case report

(4213) Views  (1118) Full article downloads

Authors: Shinichiro Ryuge, Shi-Xu Jiang, Mayuko Wada, Ken Katono, et al.

Published Date July 2009 Volume 2009:3 Pages 213 - 217
DOI: http://dx.doi.org/10.2147/DDDT.S6423

Shinichiro Ryuge1, Shi-Xu Jiang2, Mayuko Wada1, Ken Katono1, Maiko Iwasaki1, Akira Takakura1, Sakiko Otani1, Yuka Kimura1, Tomoya Fukui1, Masanori Yokoba1, Masaru Kubota1, Masato Katagiri1, Kazusige Hayakawa3, Noriyuki Masuda1

1Department of Respiratory Medicine, 2Department of Pathology, 3Department of Radiology, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan

Abstract: Large-cell neuroendocrine carcinoma (LCNEC) is a relatively uncommon variant of non-small cell lung cancer. Since the biological characteristics of LCNEC are similar to those of small cell lung cancer, LCNEC is usually treated with chemotherapy regimens used for small cell lung cancer. However, the outcomes are usually dismal. Here, we report a patient with LCNEC (a metastasis to the brain). After whole brain irradiation, he received a combination of amrubicin and irinotecan chemotherapy, and has been relapse-free for two years. This treatment regimen may be beneficial for patients with advanced LCNEC.

Keywords: large-cell neuroendocrine carcinoma, chemotherapy, amrubicin, irinotecan, lung cancer

General overview: Large-cell neuroendocrine carcinoma (LCNEC) is a relatively uncommon variant of non-small cell lung cancer. Since LCNEC has similar biological characteristics and aggressive clinical features to small cell lung cancer (SCLC), LCNEC is usually treated with combination regimens used for SCLC. However, the outcomes are far from satisfactory. We report a 66-year-old LCNEC patient with brain metastasis, who achieved a complete response to the whole brain irradiation followed by a combination of amrubicin and irinotecan. Both drugs are active against several malignant diseases, especially small cell lung cancer. At present, he has been without relapse for two years. The results obtained with this regimen may add the new regimen for treatment of patients with advanced LCNEC.






 

Other articles by Dr Noriyuki Masuda



Readers of this article also read:

Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Critical appraisal of the role of glucosamine and chondroitin in the management of osteoarthritis of the knee
Ego mechanisms of defense are associated with patients’ preference of treatment modality independent of psychological distress in end-stage renal disease
Can a gentamicin-specific chart reduce neonatal medication errors?
Health literacy and health seeking behavior among older men in a middle-income nation
Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered
Dashboards in neonatology
Anesthesiologists’ perception of patients’ anxiety under regional anesthesia
Everolimus-eluting stents: update on current clinical studies
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University